Exclusive: AstraZeneca U.S. COVID-19 vaccine trial may resume as soon as this week - sources

By Julie Steenhuysen and Marisa Taylor CHICAGO/WASHINGTON (Reuters) - AstraZeneca Plc's COVID-19 vaccine trial in the United States is expected to resume as early as this week after the U.S. Food and Drug Administration completed its review of a serious illness, four sources told Reuters. AstraZeneca's large, late-stage U.S

Reuters October 21, 2020 00:05:25 IST
Exclusive: AstraZeneca U.S. COVID-19 vaccine trial may resume as soon as this week - sources

COVID-19 vaccine trial may resume as soon as this week - sources" src="https://images.firstpost.com/wp-content/uploads/reuters/10-2020/21/2020-10-20T164708Z_1_LYNXMPEG9J1E1_RTROPTP_2_HEALTH-CORONAVIRUS-ASTRAZENECA-USA.jpg" alt="Exclusive AstraZeneca US COVID19 vaccine trial may resume as soon as this week sources" width="300" height="225" />

By Julie Steenhuysen and Marisa Taylor

CHICAGO/WASHINGTON (Reuters) - AstraZeneca Plc's COVID-19 vaccine trial in the United States is expected to resume as early as this week after the U.S. Food and Drug Administration completed its review of a serious illness, four sources told Reuters.

AstraZeneca's large, late-stage U.S. trial has been on hold since Sept. 6, after a participant in the company's UK trial fell ill with what was suspected to be a rare spinal inflammatory disorder called transverse myelitis.

The sources, who were briefed on the matter but asked to remain anonymous, said they have been told the trial could resume later this week. It was unclear how the FDA would characterize the illness, they said.

The FDA did not respond to a request for comment.

The agency is requiring researchers conducting the trial to add information about the incident to consent forms signed by study participants, according to one of the sources.

UK regulatory officials previously reviewed the illness and determined there was “insufficient evidence to say for certain” that it was or was not related to the vaccine. It permitted the trial to resume enrolling participants in the UK, according to a draft of the updated consent form shared with Reuters.

“In this case, after considering the information, the independent reviewers and MHRA (Medicines and Healthcare products Regulatory Agency) recommended that vaccinations should continue,” the draft consent form stated. “Close monitoring of the affected individual and other participants will be continued.”

Regulators in Brazil, India and South Africa also previously allowed AstraZeneca to resume its vaccine trials there.

Responding to a request, British regulators shared with Reuters a draft of a form letter to UK vaccine trial participants, dated Oct. 14 and signed by the Oxford COVID-19 Vaccine Team. It says the U.S. FDA had “completed their analysis” and said vaccination in the United States would resume shortly.

FDA "has come to the same conclusion as the other drug regulators including the MHRA," the letter states. The regulator, Health Research Authority, did not say if the letter had been sent or immediately respond to questions about it.

An AstraZeneca spokeswoman said the communication is not from the company and it "cannot verify the content," referring to the draft letter to patients.

"We also cannot comment on a pending FDA decision," she said.

(Reporting by Julie Steenhuysen and Marisa Taylor; Editing by Bill Berkrot)

This story has not been edited by Firstpost staff and is generated by auto-feed.

Updated Date:

TAGS:

Find latest and upcoming tech gadgets online on Tech2 Gadgets. Get technology news, gadgets reviews & ratings. Popular gadgets including laptop, tablet and mobile specifications, features, prices, comparison.

also read

IAEA and U.S. pressure Iran over uranium particles at 'atomic warehouse'
World

IAEA and U.S. pressure Iran over uranium particles at 'atomic warehouse'

VIENNA (Reuters) - The U.N. nuclear watchdog and the United States pressured Iran on Wednesday to finally explain the origin of uranium particles found almost two years ago at an old but undeclared site that Israel has called a "secret atomic warehouse". Israeli Prime Minister Benjamin Netanyahu drew attention to the Turqazabad site in Tehran in a speech to the United Nations in September 2018, urging the International Atomic Energy Agency to visit it

Sri Lanka's Gotabaya says has reassembled nation's intelligence network
World

Sri Lanka's Gotabaya says has reassembled nation's intelligence network

NEW DELHI (Reuters) - Sri Lankan President Gotabaya Rajapaksa said on Wednesday he had delivered on a key election promise to rebuild the island nation's intelligence network in the year since assuming office.

Pole and Chinese citizen indicted in Warsaw for spying
World

Pole and Chinese citizen indicted in Warsaw for spying

WARSAW (Reuters) - Polish authorities said on Wednesday a former secret service agent and a Chinese citizen who worked for a telecommunications company have been charged with spying for China. Reuters previously reported on the allegations against an employee of Huawei and a former Polish domestic intelligence operative who were being investigated by the Warsaw government for suspected espionage